ICCC

ImmuCell Corporation

Price

$10.01

return (12m)

63.56%

p/e

112.10

p/bv

2.82

DIVIDEND YIELD

0.00%

ICCC price

ImmuCell

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ICCC

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-9.00%

3 months

-2.25%

1 year

63.56%

2 years

163.42%

5 years

10.73%

10 years

41.18%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ICCC

Valuation

P/E

112.10

Sector -4.26

Industry -4.26

P/BV

2.82

Sector 2.11

Industry 2.11

P/Revenue (PSR)

2.89

Sector 2.08

Industry 2.08

EV/EBITDA

Sector -546.19

Industry -546.19

EV/EBIT

Sector -37.31

Industry -37.31

P/EBITDA

Sector -50.76

Industry -50.76

P/EBIT

Sector -39.62

Industry -39.62

P/Total Assets

1.90

Sector 1.25

Industry 1.25

P/Net Current Assets

15.22

Sector -5.47

Industry -5.47

P/Working Capital

5.32

Sector -1.10

Industry -1.10

EPS

0.09

Sector -1.94

Industry -1.94

BVPS

3.49

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

40.31%

Sector 38.90%

Industry 38.90%

EBITDA Margin

0.00%

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

0.00%

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

12.61%

Sector -36.74%

Industry -36.74%

Net Profit Margins

2.57%

Sector -37.51%

Industry -37.51%

Asset Turnover

0.15

Sector 0.03

Industry 0.03

Profitability

ROE

2.52%

Sector -61.50%

Industry -61.50%

ROA

1.69%

Sector -63.85%

Industry -63.85%

ROIC

0.00%

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

4.75

Sector 2.89

Industry 2.89

Net Debt / EBITDA

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

Sector -10.24

Industry -10.24

Net Debt / Equity

0.22

Sector -0.60

Industry -0.60

Gross Debt / Equity

0.22

Sector -0.83

Industry -0.83

Equity/Assets

0.67

Sector 0.43

Industry 0.43

Liabilities/Assets

0.33

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

9.79%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF ImmuCell ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$10.01

Fair Value

$2.66

Upside Return potential.

-73.44%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ICCC

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ICCC ImmuCell Corporation	$10.01	64.10%	0.00%	112.10	2.82	2.52%	2.57%
JNJ Johnson & Johnson	$266.50	55.29%	1.93%	31.09	7.70	24.76%	21.48%
PFE Pfizer Inc.	$27.87	21.03%	6.26%	35.86	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$256.91	27.42%	2.58%	74.16	-78.93	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.62	-14.65%	3.95%	11.47	6.09	53.11%	35.32%
MRK Merck & Co. Inc.	$147.77	82.61%	2.24%	116.78	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$161.98	3.71%	1.93%	24.59	5.10	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.29	45.78%	3.73%	14.81	6.16	41.55%	18.85%
ZTS Zoetis Inc.	$76.84	-49.43%	2.67%	12.20	10.25	84.02%	27.77%
REGN Regeneron Pharmaceuticals Inc.	$792.43	37.47%	0.44%	19.71	2.69	13.65%	27.86%
AMGN Amgen Inc.	$432.42	55.55%	2.22%	27.25	20.39	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$105.00	43.48%	0.00%	30.73	88.55	288.14%	24.86%
MCK McKesson Corporation	$897.16	31.93%	0.38%	19.60	-26.88	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$542.40	39.41%	0.00%	31.57	6.87	21.76%	35.00%
CAH Cardinal Health Inc.	$235.19	59.60%	0.88%	35.20	-20.39	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.29	3.26%	0.00%	12.32	2.23	18.14%	18.89%
BIIB Biogen Inc.	$217.24	59.31%	0.00%	38.68	1.71	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ICCC Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT ImmuCell

ImmuCell Corporation

Average Investor10 user rating

4.0 (1 people)

United States

44 years

Founded: 1982

1987

Time since IPO - 39 years

61

Employees

ImmuCell Corporation (United States) is listed on the Nasdaq and has a market capitalization of $88.56 million, with shareholders equity totaling $31.38 million.

The company employs approximately 61 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, ImmuCell Corporation reported $30.69 million in revenue, generating net income of $790.00 Thousand.

Key financial metrics include a P/E ratio of 112.10, a price-to-book (P/B) ratio of 2.82, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ICCC.

Market cap

$88.56 million

Net worth

$31.38 million

$31,380,000.00

Assets

$46.63 million

$46,630,000.00

Total Shares Outstanding

9.00 million

9,000,000

Average Daily Trading Volume

$32.90 Thousand

$32,903.34

Sector

Health Care

Industry

Biotechnology

ICCC

ICCC revenue and profits

Financial Results ICCC

DRAG THE FRAME TO SEE MORE DATA

ICCC cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$897.16 31,33% (12M)

P/E

19.60

0.38%

ROE

-137.16%

P/BV

-26.88

CAH - Cardinal Health

$235.19 60,10% (12M)

P/E

35.20

0.88%

ROE

-57.93%

P/BV

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12M)

P/E

31.09

1.93%

ROE

24.76%

P/BV

7.70

ABBV - AbbVie

$256.91 26,00% (12M)

P/E

74.16

2.58%

ROE

-106.44%

P/BV

-78.93

MRK - Merck & Co.

$147.77 82,50% (12M)

P/E

116.78

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$161.98 3,46% (12M)

P/E

24.59

1.93%

ROE

20.74%

P/BV

5.10

PFE - Pfizer

$27.87 22,54% (12M)

P/E

35.86

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$897.16 31,33% (12 M)

P/L

19.60

0.38%

ROE

-137.16%

P/VP

-26.88

CAH - Cardinal Health

$235.19 60,10% (12 M)

P/L

35.20

0.88%

ROE

-57.93%

P/VP

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12 M)

P/L

31.09

1.93%

ROE

24.76%

P/VP

7.70

ABBV - AbbVie

$256.91 26,00% (12 M)

P/L

74.16

2.58%

ROE

-106.44%

P/VP

-78.93

MRK - Merck & Co.

$147.77 82,50% (12 M)

P/L

116.78

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$161.98 3,46% (12 M)

P/L

24.59

1.93%

ROE

20.74%

P/VP

5.10

PFE - Pfizer

$27.87 22,54% (12 M)

P/L

35.86

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of ImmuCell (ICCC) today?

A cotação de ImmuCell (ICCC) hoje está em US$ 10.01, com uma variação de 63.56% em relação ao último ano. A cotação de ImmuCell (ICCC) iniciou o ano negociando na casa dos US$ 6.15 e hoje está em US$ 10.01. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de ImmuCell (ICCC) e dados de ações do Ibovespa e mercados internacionais.

Quando ImmuCell (ICCC) paga dividendos?

ImmuCell (ICCC) não distribuiu dividendos no último ano.

Is ImmuCell (ICCC) a good investment?

Atualmente, ImmuCell (ICCC) está cotada a US$ 10.01, com um P/L de 112.10, representando um desvio de 250% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 63.56 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 63.56%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy ImmuCell (ICCC) stock?

Investir em ações de ImmuCell (ICCC) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of ImmuCell (ICCC) yield today?

A rentabilidade de ImmuCell (ICCC) foi de -9.00% no último mês, 63.56% no último ano e 10.73% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de ImmuCell (ICCC) hoje, o investimento total seria de US$ 1,001.00, com base na cotação atual de US$ 10.01.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 1,637.24
Em 5 anos: US$ 1,108.41
Em 10 anos: US$ 1,413.21

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ICCC

ImmuCell Corporation

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ICCC

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING ICCC WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT ImmuCell

ImmuCell Corporation

United States

44 years

1987

61

PROFIT X PRICE ICCC

Financial Results ICCC

ICCC cash flow

Asset, Revenue and Profit Growth - ICCC

ICCC balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions